FGL

What NCAM does and why mimicking it is interesting. The neural cell adhesion molecule holds neurons together and, more importantly, signals through the fibroblast growth factor receptor to drive neurite outgrowth, synapse formation and plasticity. NCAM function declines in ageing and is disrupted in several psychiatric and neurodegenerative conditions. FGL is a synthetic peptide reproducing the NCAM sequence that binds FGFR, so it engages that signalling without requiring the whole adhesion molecule [6].

The rodent results, which are the reason to take it seriously. They come from different laboratories and different models:

• Ageing rats subjected to chronic stress followed by intermittent stress lost spatial memory and newborn hippocampal cells; FGL prevented both [1].
• Rats given neonatal phencyclidine - a developmental model relevant to schizophrenia - showed impaired spatial learning and memory, which FGL reversed [2].
• Young adult rats given amyloid-beta lost CA1 pyramidal cells; systemic FGL alleviated that loss [3].
• FGL mobilises neural stem cells both in vitro and in vivo [4].
• Separately from all of the above, it has an anti-inflammatory action [5].

Five models, several groups, one direction. That is a stronger preclinical package than most compounds in this group, and it is worth saying so plainly.

What has not happened. No human trial. No pharmacokinetic study. No safety data. A 2016 review framed targeting NCAM as a pharmacological approach to dysfunctional brain plasticity and surveyed the compounds available [6] - which is the position the field has stayed in.

How to weigh it. Consistent rodent results across independent models raise the prior that something real is happening. They do not establish that it happens in humans, at a tolerable dose, by an achievable route, for long enough to matter. Every compound on this site with human trials had preclinical packages at least this good, and most of them failed anyway.

NCAM's plasticity signalling runs through the fibroblast growth factor receptor rather than through adhesion alone. FGL copies the NCAM region responsible for that interaction, binding FGFR and triggering the downstream cascade - receptor autophosphorylation, PLCgamma and MAPK signalling - that produces neurite outgrowth and synaptic change [6].

The neurogenic and neuroprotective results follow from that: FGFR signalling supports survival and proliferation of neural progenitors, which is consistent with the stem cell mobilisation finding [4] and with protection of newborn hippocampal cells under stress [1].

The anti-inflammatory action is described as a novel and separate role [5], which complicates the clean story: if the peptide has at least two mechanisms, the contribution of each to the behavioural results is unresolved, and no study has separated them.

The practical unknown is exposure. The amyloid study used systemic administration and saw central effects [3], which implies the peptide or something derived from it reaches the brain - but nobody has measured how much, or what form.

A synthetic peptide, administered systemically in the rodent work [1][2][3]. There is no human formulation and no published route selection, stability or delivery work.

No human safety data exist, and the rodent studies were designed to measure cognition and histology rather than toxicity. None reported adverse findings, but none was looking systematically.

Two mechanism-derived considerations. Activating FGFR signalling promotes proliferation, and fibroblast growth factor pathways are implicated in several cancers - a consideration for any sustained FGFR agonist that no study of FGL has addressed. And a compound with both plasticity-promoting and anti-inflammatory actions [5] has two routes to unintended effects, neither characterised over a long exposure.

The general point applies: consistent efficacy across models says nothing about the safety margin, because none of these studies measured one.

No interaction studies exist. The comparisons in the literature are between FGL and the injury models it was tested against, not with other compounds.